In the preceding three months, 17 analysts have released ratings for UnitedHealth Group UNH, presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 5 | 12 | 0 | 0 | 0 |
Last 30D | 0 | 1 | 0 | 0 | 0 |
1M Ago | 0 | 1 | 0 | 0 | 0 |
2M Ago | 5 | 7 | 0 | 0 | 0 |
3M Ago | 0 | 3 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for UnitedHealth Group, presenting an average target of $610.76, a high estimate of $680.00, and a low estimate of $559.00. Observing a 6.57% increase, the current average has risen from the previous average price target of $573.12.
Deciphering Analyst Ratings: An In-Depth Analysis
A comprehensive examination of how financial experts perceive UnitedHealth Group is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Sarah James | Cantor Fitzgerald | Maintains | Overweight | $591.00 | $591.00 |
Sarah James | Cantor Fitzgerald | Maintains | Overweight | $591.00 | $591.00 |
Kevin Caliendo | UBS | Raises | Buy | $680.00 | $640.00 |
David Toung | Argus Research | Raises | Buy | $600.00 | $570.00 |
Gary Taylor | TD Cowen | Raises | Buy | $601.00 | $546.00 |
Andrew Mok | Barclays | Raises | Overweight | $604.00 | $560.00 |
Sarah James | Cantor Fitzgerald | Maintains | Overweight | $591.00 | $591.00 |
Stephen Baxter | Wells Fargo | Raises | Overweight | $630.00 | $525.00 |
David Macdonald | Truist Securities | Raises | Buy | $640.00 | $600.00 |
Ben Hendrix | RBC Capital | Raises | Outperform | $615.00 | $555.00 |
David Windley | Jefferies | Raises | Buy | $647.00 | $481.00 |
Michael Ha | Baird | Raises | Outperform | $640.00 | $597.00 |
Ricky Goldwasser | Morgan Stanley | Raises | Overweight | $615.00 | $595.00 |
Sarah James | Cantor Fitzgerald | Maintains | Overweight | $591.00 | $591.00 |
Sarah James | Cantor Fitzgerald | Maintains | Overweight | $591.00 | $591.00 |
Lisa Gill | JP Morgan | Raises | Overweight | $559.00 | $546.00 |
Michael Ha | Baird | Announces | Outperform | $597.00 | - |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to UnitedHealth Group. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of UnitedHealth Group compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of UnitedHealth Group's stock. This comparison reveals trends in analysts' expectations over time.
For valuable insights into UnitedHealth Group's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on UnitedHealth Group analyst ratings.
Discovering UnitedHealth Group: A Closer Look
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 50 million members globally, including 1 million outside the us as June 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Financial Milestones: UnitedHealth Group's Journey
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: UnitedHealth Group's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 6.61%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: UnitedHealth Group's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 4.31%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.79%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): UnitedHealth Group's ROA excels beyond industry benchmarks, reaching 1.48%. This signifies efficient management of assets and strong financial health.
Debt Management: UnitedHealth Group's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.84, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
How Are Analyst Ratings Determined?
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.